Dosimetric impact of adaptive proton therapy in head and neck cancer - A review.
Adaptive proton therapy
Dosimetric impact
Head and neck cancer
Intensity modulated proton therapy
Review
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
12
12
2022
revised:
10
02
2023
accepted:
12
02
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Intensity Modulated Proton Therapy (IMPT) in head and neck cancer (HNC) is susceptible to anatomical changes and patient set-up inaccuracies during the radiotherapy course, which can cause discrepancies between planned and delivered dose. The discrepancies can be counteracted by adaptive replanning strategies. This article reviews the observed dosimetric impact of adaptive proton therapy (APT) and the timing to perform a plan adaptation in IMPT in HNC. A literature search of articles published in PubMed/MEDLINE, EMBASE and Web of Science from January 2010 to March 2022 was performed. Among a total of 59 records assessed for possible eligibility, ten articles were included in this review. Included studies reported on target coverage deterioration in IMPT plans during the RT course, which was recovered with the application of an APT approach. All APT plans showed an average improved target coverage for the high- and low-dose targets as compared to the accumulated dose on the planned plans. Dose improvements up to 2.5 Gy (3.5 %) and up to 4.0 Gy (7.1 %) in the D98 of the high- and low dose targets were observed with APT. Doses to the organs at risk (OARs) remained equal or decreased slightly after APT was applied. In the included studies, APT was largely performed once, which resulted in the largest target coverage improvement, but eventual additional APT improved the target coverage further. There is no data showing what is the most appropriate timing for APT. APT during IMPT for HNC patients improves target coverage. The largest improvement in target coverage was found with a single adaptive intervention, and an eventual second or more frequent APT application improved the target coverage further. Doses to the OARs remained equal or decreased slightly after applying APT. The most optimal timing for APT is yet to be determined.
Sections du résumé
Background
UNASSIGNED
Intensity Modulated Proton Therapy (IMPT) in head and neck cancer (HNC) is susceptible to anatomical changes and patient set-up inaccuracies during the radiotherapy course, which can cause discrepancies between planned and delivered dose. The discrepancies can be counteracted by adaptive replanning strategies. This article reviews the observed dosimetric impact of adaptive proton therapy (APT) and the timing to perform a plan adaptation in IMPT in HNC.
Methods
UNASSIGNED
A literature search of articles published in PubMed/MEDLINE, EMBASE and Web of Science from January 2010 to March 2022 was performed. Among a total of 59 records assessed for possible eligibility, ten articles were included in this review.
Results
UNASSIGNED
Included studies reported on target coverage deterioration in IMPT plans during the RT course, which was recovered with the application of an APT approach. All APT plans showed an average improved target coverage for the high- and low-dose targets as compared to the accumulated dose on the planned plans. Dose improvements up to 2.5 Gy (3.5 %) and up to 4.0 Gy (7.1 %) in the D98 of the high- and low dose targets were observed with APT. Doses to the organs at risk (OARs) remained equal or decreased slightly after APT was applied. In the included studies, APT was largely performed once, which resulted in the largest target coverage improvement, but eventual additional APT improved the target coverage further. There is no data showing what is the most appropriate timing for APT.
Conclusion
UNASSIGNED
APT during IMPT for HNC patients improves target coverage. The largest improvement in target coverage was found with a single adaptive intervention, and an eventual second or more frequent APT application improved the target coverage further. Doses to the OARs remained equal or decreased slightly after applying APT. The most optimal timing for APT is yet to be determined.
Identifiants
pubmed: 36860581
doi: 10.1016/j.ctro.2023.100598
pii: S2405-6308(23)00023-X
pmc: PMC9969246
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100598Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Head Neck. 2007 Apr;29(4):387-400
pubmed: 16358297
Int J Part Ther. 2021 Mar 15;7(4):29-41
pubmed: 33829071
Med Dosim. 2020 Winter;45(4):384-392
pubmed: 32660887
Phys Med Biol. 2022 Jan 17;67(2):
pubmed: 34874302
J Appl Clin Med Phys. 2021 Jan;22(1):174-183
pubmed: 33338323
Phys Med Biol. 2021 Feb 25;66(5):
pubmed: 33503592
Radiother Oncol. 2020 Dec;153:88-96
pubmed: 32579998
J Med Internet Res. 2021 Jul 12;23(7):e26151
pubmed: 34255661
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):994-1003
pubmed: 28916139
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):960-70
pubmed: 15234029
Radiother Oncol. 2021 Jun;159:39-47
pubmed: 33741469
Cancers (Basel). 2021 Nov 28;13(23):
pubmed: 34885100
Acta Oncol. 2018 Oct;57(10):1284-1292
pubmed: 30289291
Phys Med Biol. 2018 Apr 20;63(8):085018
pubmed: 29595145
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):590-6
pubmed: 21310549
Radiat Oncol. 2014 Aug 11;9:175
pubmed: 25112458
J Appl Clin Med Phys. 2022 May;23(5):e13550
pubmed: 35128788
Radiother Oncol. 2019 Feb;131:127-134
pubmed: 30773179
Br J Radiol. 2020 Mar;93(1107):20190594
pubmed: 31647313
Med Phys. 2015 Aug;42(8):4449-59
pubmed: 26233175
Radiother Oncol. 2015 Jun;115(3):285-94
pubmed: 26094076
Radiat Oncol. 2016 Apr 30;11:64
pubmed: 27129305
Head Neck Tumor Segm Chall (2021). 2022;13209:121-132
pubmed: 35399869
Phys Med Biol. 2018 Dec 19;64(1):015004
pubmed: 30524097
Phys Med Biol. 2020 Dec 04;65(24):
pubmed: 32580174
Phys Med Biol. 2018 Nov 12;63(22):22TR02
pubmed: 30418942
Radiother Oncol. 2011 Dec;101(3):376-82
pubmed: 21663988
Oncologist. 2011;16(3):366-77
pubmed: 21349950
Int J Part Ther. 2017 Fall;4(2):26-34
pubmed: 31773006
J Appl Clin Med Phys. 2017 Nov;18(6):104-113
pubmed: 28921843
Clin Transl Radiat Oncol. 2022 Jun 18;36:47-55
pubmed: 35782963
Phys Med Biol. 2018 Jan 11;63(2):025020
pubmed: 29160775
Phys Med Biol. 2021 Nov 15;66(22):
pubmed: 34710858
Semin Radiat Oncol. 2018 Jan;28(1):53-63
pubmed: 29173756
Radiother Oncol. 2020 Jan;142:124-132
pubmed: 31564553